TransDigm Group heads into late August with a tug-of-war between a notable shift in options sentiment, a founder trimming at the highs, and a Street that remains divided after a disappointing earnings print earlier this month.
The most striking data point this week is in the options market. Positioning has turned sharply less defensive — the put/call ratio dropped to 1.05 on Tuesday, more than two standard deviations below its 20-day average of 1.47. That's the most call-heavy reading in several months, a notable reversal after weeks of elevated put demand. The context matters: the PCR had been running persistently above 1.6 through most of July, suggesting investors were hedging into the Q3 report. That protective posture is now unwinding fast, even as the stock is down 3.3% on the week to $1,192.60.
Short interest offers little in the way of drama. Bears have been steadily covering — positions have fallen roughly 28% over the past month to 1.4% of the free float, barely a rounding error for a name of TDG's stature. The lending market confirms the lack of short conviction: borrow availability is essentially uncapped, with a 47 million share inventory dwarfing the 814,000 shares currently short. Cost to borrow has ticked up 55% on the week to 0.49%, but from a very low base — this is a cheap, freely available borrow with no squeeze dynamics whatsoever. The short story here is one of continued retreat, not escalation.
The more interesting signal comes from the founder's chair. Walter Howley sold roughly 4,200 shares across ten transactions on August 18, raising just over $4.1 million at prices clustered between $1,225 and $1,238 — well above the current $1,192 handle. On a 90-day net basis, insiders are actually net buyers by about 13,900 shares worth $17.2 million, so Howley's clip doesn't reverse the broader insider picture. Still, a founder selling into strength, days after a weak earnings reception, is worth flagging even if the significance score on each individual trade was low.
The Street is genuinely split. UBS raised its target to $1,695 after the August 4 print and held its Buy rating — calling out the 160 basis point margin expansion to 54.2% and continued strength in commercial aftermarket and defense. Stifel moved the other way, downgrading to Hold and cutting its target to $1,405, pointing to the below-consensus FY2026 EBITDA guide of $5.15 billion and the dilutive drag from the Simmonds acquisition. Morgan Stanley had already stepped back in July, cutting to Equal-Weight with a $1,345 target from $1,680. The mean target of $1,523 implies roughly 28% upside from here, but the dispersion is wide — Wells Fargo initiated in April at $1,200, barely above spot. The ORTEX short score is a benign 29.8, having eased from just above 30 a week ago, while EPS momentum ranks in the 75th percentile on a 30-day view — a sign that estimate revisions, while choppy, are still tilted positive.
Sector peers have had a rough week broadly. GE fell 6.8%, RTX lost 6.7%, LOAR dropped 4.7%, and HEI shed 4.6% — TDG's 3.3% decline looks almost orderly by comparison. The next scheduled earnings event is November 10, giving the stock roughly ten weeks to find a cleaner narrative. Between now and then, the question is whether the options shift toward calls is a genuine sentiment reset or simply a mechanical unwinding of hedges placed ahead of last month's report — the put/call ratio's next move will be the clearest gauge of how conviction is rebuilding.
See the live data behind this article on ORTEX.
Open TDG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
